Cochrane · systematic review · CD011594
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
Ni, H, Moe, S, Soe, Z, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
21
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 4.8%Moderate 11 · 52.4%High 9 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fixed‐dose combination aclidinium/formoterol compared to aclidinium alone for chronic obstructive pulmonary disease (COPD)
Population: people with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations requiring steroids or antibiotics or both: number of participants Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 0.95 [0.71, 1.27] | 2 studies · 2156 participants | Moderate Downgraded: imprecision |
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 1.17 [0.97, 1.41] | 2 studies · 2002 participants | Moderate Downgraded: imprecision |
Non‐fatal serious adverse events Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 1.19 [0.79, 1.8] | 3 studies · 2473 participants | Moderate Downgraded: imprecision |
Hospital admissions due to exacerbations: number of participants Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 0.62 [0.29, 1.29] | 2 studies · 2156 participants | Moderate Downgraded: imprecision |
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 1.34 [1.11, 1.62] | 2 studies · 2013 participants | High |
Change in lung function: from baseline in trough FEV1 (L) Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | no estimate extracted | 3 studies · 2333 participants | High |
Adverse events (not including serious adverse events): number of participants Fixed‐dose combination aclidinium/formoterol vs aclidinium alone | OR 0.95 [0.76, 1.18] | 3 studies · 2473 participants | Moderate Downgraded: imprecision |
Fixed‐dose combination aclidinium/formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)
Population: people with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations requiring steroids or antibiotics or both: number of participants Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 0.78 [0.62, 0.99] | 3 studies · 2694 participants | High |
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 1.15 [0.89, 1.5] | 1 study · 1000 participants | Low Downgraded: imprecision |
Non‐fatal serious adverse events Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 1.15 [0.82, 1.61] | 5 studies · 3140 participants | Moderate Downgraded: imprecision |
Hospital admissions due to exacerbations: number of participants Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 0.76 [0.45, 1.28] | 3 studies · 2694 participants | Moderate Downgraded: imprecision |
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 1.3 [1.07, 1.56] | 2 studies · 2010 participants | High |
Change in lung function: from baseline in trough FEV1 (L) Fixed‐dose combination aclidinium/formoterol vs formoterol | no estimate extracted | 4 studies · 2411 participants | High |
Adverse events (not including serious adverse events): number of participants Fixed‐dose combination aclidinium/formoterol vs formoterol | OR 0.78 [0.65, 0.93] | 5 studies · 3140 participants | High |
Fixed‐dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)
Population: people with chronic obstructive pulmonary disease (COPD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations requiring steroids or antibiotics or both: number of participants Fixed‐dose combination aclidinium/formoterol vs placebo | OR 0.82 [0.6, 1.12] | 2 studies · 1960 participants | Moderate Downgraded: imprecision |
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score Fixed‐dose combination aclidinium/formoterol vs placebo | OR 1.72 [1.39, 2.13] | 2 studies · 1823 participants | High |
Non‐fatal serious adverse events Fixed‐dose combination aclidinium/formoterol vs placebo | OR 1.12 [0.72, 1.74] | 4 studies · 2527 participants | Moderate Downgraded: imprecision |
Hospital admissions due to exacerbations: number of participants Fixed‐dose combination aclidinium/formoterol vs placebo | OR 0.55 [0.25, 1.18] | 2 studies · 1960 participants | Moderate Downgraded: imprecision |
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) Fixed‐dose combination aclidinium/formoterol vs placebo | OR 2.51 [2.02, 3.11] | 2 studies · 1832 participants | High |
Change in lung function: from baseline in trough FEV1 (L) Fixed‐dose combination aclidinium/formoterol vs placebo | no estimate extracted | 3 studies · 2137 participants | High |
Adverse events (not including serious adverse events): number of participants Fixed‐dose combination aclidinium/formoterol vs placebo | OR 0.97 [0.76, 1.22] | 4 studies · 2527 participants | Moderate Downgraded: imprecision |